What Is Ipamorelin? Uses, Benefits, Safety, FDA Status, and Evidence
Medical review note: This article is for educational purposes only and does not provide medical advice. Ipamorelin is not FDA-approved for human therapeutic use. Products sold online as ipamorelin, ipamorelin acetate, or “research use only” ipamorelin may carry serious safety, quality, and legal risks.
Quick answer
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue. It mimics ghrelin and binds to the growth hormone secretagogue receptor, also called the ghrelin receptor or GHSR, which can stimulate the pituitary gland to release growth hormone. Small human studies show that ipamorelin can increase growth hormone levels, but it is not FDA-approved, has limited clinical-outcome evidence, and is prohibited in competitive sport. FDA has also raised concerns about compounded ipamorelin acetate because of potential immunogenicity, aggregation, peptide-related impurities, and the complexity of peptide characterization.
Key facts about Ipamorelin
| Question | Answer |
|---|---|
| What is ipamorelin? | A synthetic pentapeptide growth hormone secretagogue. |
| Other names | Ipamorelin acetate, NNC 26-0161, growth hormone-releasing peptide. |
| Peptide class | Growth hormone secretagogue / ghrelin receptor agonist. |
| Main mechanism | Mimics ghrelin and activates the growth hormone secretagogue receptor, stimulating pituitary growth hormone release. |
| FDA-approved? | No. Ipamorelin is not an FDA-approved drug. |
| Main studied uses | Growth hormone stimulation, pharmacokinetic/pharmacodynamic studies, and preclinical growth-hormone-related research. |
| Human evidence level | Limited. Small human studies show GH release, but strong clinical-outcome evidence is lacking. |
| Animal/lab evidence level | Preclinical studies support growth hormone secretagogue activity. |
| Common online claims | “Increases HGH,” “fat loss,” “muscle growth,” “recovery,” “anti-aging,” “better sleep,” “body recomposition.” |
| Sports status | Prohibited in and out of competition as a growth hormone secretagogue. |
| Main safety concern | FDA-identified concerns around immunogenicity, aggregation, peptide-related impurities, unnatural amino acids, API characterization, and unapproved online products. |
What is ipamorelin?
Ipamorelin is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. A growth hormone secretagogue is a compound that stimulates the body to release growth hormone.
The National Cancer Institute Drug Dictionary defines ipamorelin as a pentapeptide and ghrelin mimetic with growth hormone-releasing activity. It says ipamorelin binds to the ghrelin receptor, also called the growth hormone secretagogue receptor, in the brain and selectively stimulates growth hormone release from the pituitary gland.
Ipamorelin is commonly grouped with peptides such as CJC-1295 and sermorelin, but it is not the same type of molecule.
| Compound | Category | Main distinction |
|---|---|---|
| Ipamorelin | Ghrelin receptor agonist / growth hormone secretagogue | Stimulates GH release through ghrelin/GHSR signaling. |
| Sermorelin | GHRH analog | Stimulates GH release through GHRH receptor signaling. |
| CJC-1295 | Long-acting GHRH analog | Designed to prolong GH/IGF-1 stimulation through GHRH-related mechanisms. |
| Tesamorelin | GHRH analog | FDA-approved for excess abdominal fat in adults with HIV and lipodystrophy. |
The key distinction:
Ipamorelin can stimulate growth hormone release, but that does not make it an FDA-approved anti-aging, fat-loss, recovery, or muscle-building treatment.
How does ipamorelin work?
Ipamorelin mimics ghrelin-like signaling and activates the growth hormone secretagogue receptor. This can stimulate the pituitary gland to release growth hormone.
In plain English:
Ipamorelin tells the body to release more of its own growth hormone rather than directly supplying recombinant human growth hormone.
Ipamorelin has often been described as relatively selective for growth hormone release compared with some older growth hormone-releasing peptides. A PubMed-indexed study described ipamorelin as a potent synthetic pentapeptide with distinct and specific growth hormone-releasing properties.
But mechanism is not proof.
A proposed hormonal mechanism does not prove that ipamorelin reverses aging, builds muscle, burns fat, improves sleep, accelerates recovery, heals injuries, or safely improves performance in healthy adults. The quality of evidence depends on controlled human studies in the specific population and outcome being claimed.
What is ipamorelin used for?
Ipamorelin is commonly discussed for growth hormone optimization, anti-aging, fat loss, muscle growth, sleep, recovery, and body composition. These uses differ sharply in evidence quality.
| Use | Evidence level | What is known | What is not known |
|---|---|---|---|
| Growth hormone stimulation | Limited human evidence | Human pharmacokinetic/pharmacodynamic studies show ipamorelin can stimulate GH release. | Long-term safety and clinical utility are not established. |
| Growth hormone deficiency | Not established | Ipamorelin stimulates GH release, but it is not FDA-approved for GHD. | Strong clinical effectiveness data for GHD are lacking. |
| Anti-aging | Unsupported | Common clinic and online claim. | No strong clinical evidence proves anti-aging or longevity benefits. |
| Fat loss/body composition | Weak / extrapolated | GH biology may influence body composition. | Not proven as a safe or effective fat-loss treatment in healthy adults. |
| Muscle growth/recovery | Weak / extrapolated | Often marketed to athletes and bodybuilders. | Not proven for performance or recovery, and prohibited in sport. |
| Sleep improvement | Weak / anecdotal | Sometimes claimed because GH secretion and sleep biology overlap. | Strong human evidence for sleep improvement is lacking. |
| Injury recovery | Unsupported / weak | Common online claim. | Not proven as a safe injury-recovery treatment in controlled human trials. |
| Online ipamorelin products | High uncertainty | Often sold as research-use peptide products. | Quality, sterility, dosing, identity, and safety may be unknown. |
What does the research show?
Human evidence
The best human evidence for ipamorelin supports a narrow claim: it can stimulate growth hormone release.
A PubMed-indexed pharmacokinetic/pharmacodynamic study examined ipamorelin as a growth hormone-releasing peptide in healthy volunteers. The study focused on pharmacokinetics and pharmacodynamics, not broad clinical outcomes such as fat loss, muscle gain, recovery, sleep, or anti-aging.
The practical interpretation:
Ipamorelin has human evidence for growth hormone release, but that is not the same as evidence for broad wellness, anti-aging, performance, or recovery benefits.
Preclinical evidence
Ipamorelin also has animal and laboratory evidence supporting its growth hormone secretagogue activity.
A PubMed-indexed study found that growth hormone secretagogues including ipamorelin and GHRP-6 increased bone mineral content in adult female rats. This is biologically interesting, but rat bone studies do not prove that ipamorelin improves bone density, muscle growth, recovery, or body composition in humans.
The practical interpretation:
Ipamorelin has real growth hormone biology, but most online claims extrapolate far beyond the clinical evidence.
Evidence limitations
The FDA has raised concerns about ipamorelin acetate in the compounding context.
The FDA page on bulk drug substances that may present significant safety risks says compounded drugs containing ipamorelin acetate may pose immunogenicity risk for certain routes of administration because of potential aggregation or peptide-related impurities. FDA also notes that ipamorelin acetate contains unnatural amino acids, adding complexity to peptide characterization.
An FDA PCAC briefing document also discusses concerns about immunogenicity for injectable ipamorelin acetate, including aggregation, peptide-related impurities, and limitations in characterization data such as impurities, aggregates, and bacterial endotoxins.
The practical interpretation:
Ipamorelin should not be treated as a harmless wellness peptide. FDA has identified real quality and safety concerns, especially for injectable compounded products.
Evidence summary
| Claim | Evidence verdict | Explanation |
|---|---|---|
| “Ipamorelin stimulates growth hormone release.” | Supported by limited human evidence | Human PK/PD studies show ipamorelin can stimulate GH release. |
| “Ipamorelin is FDA-approved.” | False | Ipamorelin is not an FDA-approved drug. |
| “Ipamorelin treats growth hormone deficiency.” | Not established | It may stimulate GH release, but it is not FDA-approved for GHD and strong clinical effectiveness data are lacking. |
| “Ipamorelin builds muscle.” | Weak / extrapolated | Often inferred from GH biology, not proven by strong clinical outcome trials. |
| “Ipamorelin burns fat.” | Weak / extrapolated | Body-composition claims are not supported by strong approval-level evidence. |
| “Ipamorelin improves sleep.” | Weak / anecdotal | Sleep claims are common, but strong human evidence is limited. |
| “Ipamorelin reverses aging.” | Unsupported | Anti-aging and longevity claims are not established. |
| “Ipamorelin is safe because it is selective.” | Misleading | Selectivity does not eliminate safety, impurity, immunogenicity, or dosing concerns. |
| “Ipamorelin is allowed for athletes.” | False | Anti-doping authorities prohibit ipamorelin in and out of competition. |
| “Research-use ipamorelin is clinically proven.” | False | Research-use products are not FDA-approved consumer therapeutic products. |
Is ipamorelin FDA-approved?
No. Ipamorelin is not FDA-approved.
The FDA compounding safety-risk page identifies ipamorelin acetate as a substance that may pose immunogenicity risks in compounded drugs because of potential aggregation or peptide-related impurities. FDA also notes that ipamorelin acetate contains unnatural amino acids, which adds complexity to peptide characterization.
The FDA PCAC briefing document discusses concerns about injectable ipamorelin acetate, including immunogenicity, aggregation, peptide-related impurities, and limited characterization data.
The key distinction:
Ipamorelin is a biologically active growth hormone secretagogue, not an FDA-approved prescription medication.
Is ipamorelin legal?
Ipamorelin’s legal status depends on product type, intended use, and jurisdiction, but the practical answer is simple:
Ipamorelin is not an FDA-approved drug, and online availability does not mean it is legally marketed for human therapeutic use.
Some sellers market ipamorelin as a research peptide. That does not make it safe, approved, or appropriate for consumer use.
The blunt version:
Buying “research use only” ipamorelin from an online seller is not the same as receiving an FDA-approved prescription drug from a legitimate pharmacy.
Is ipamorelin banned in sports?
Yes. Ipamorelin is prohibited in sport.
Sport Integrity Australia’s ipamorelin information page states that ipamorelin is prohibited in and out of competition because it stimulates growth hormone release.
The WADA 2025 Prohibited List lists growth hormone secretagogues and their mimetics, including ipamorelin, as prohibited substances.
USADA has also described ipamorelin as a potent growth hormone secretagogue that stimulates release of human growth hormone and is used as a performance-enhancing drug.
For athletes, the answer is simple:
Do not use ipamorelin if you are subject to anti-doping rules.
Safety and side effects
Ipamorelin has real biological activity. It should not be treated like a harmless supplement.
Possible or reported concerns include:
- Injection-site reactions
- Headache
- Flushing
- Dizziness
- Nausea
- Increased appetite
- Water retention
- Changes in GH and IGF-1 signaling
- Possible glucose or metabolic effects
- Immunogenicity risk
- Peptide aggregation
- Peptide-related impurities
- Product-quality and sterility risk from online sources
- Anti-doping consequences for athletes
FDA specifically identifies immunogenicity concerns for compounded ipamorelin acetate because of possible aggregation or peptide-related impurities. FDA also notes that ipamorelin acetate contains unnatural amino acids, which makes characterization more complex.
A serious evaluation of ipamorelin should separate controlled research from online peptide products.
Ipamorelin vs similar peptides
| Compound | Category | Main difference |
|---|---|---|
| Ipamorelin | Ghrelin receptor agonist / growth hormone secretagogue | Stimulates GH release through GHSR/ghrelin receptor signaling; not FDA-approved. |
| CJC-1295 | GHRH analog | Stimulates GH through GHRH-related pathways and has longer-acting DAC forms; not FDA-approved. |
| Sermorelin | GHRH analog | Historically FDA-approved as Geref, now discontinued. |
| Tesamorelin | GHRH analog | FDA-approved as Egrifta products for excess abdominal fat in adults with HIV and lipodystrophy. |
| Ibutamoren | Oral growth hormone secretagogue | Also prohibited in sport and not the same as ipamorelin. |
| Human growth hormone | Recombinant hormone | Supplies growth hormone directly rather than stimulating endogenous release. |
| BPC-157 | Experimental repair peptide | Not a growth-hormone secretagogue. |
The key distinction:
Ipamorelin belongs in the growth hormone secretagogue category. It is not a tissue-repair peptide, GLP-1 drug, or FDA-approved anti-aging medication.
Why is ipamorelin sold as “research use only”?
Some online sellers use “research use only” language to sell ipamorelin outside normal prescription-drug channels.
That label is not a trust signal.
A serious reader should understand this distinction:
| Product type | What it means |
|---|---|
| Clinical-study ipamorelin | Controlled research product used under study conditions. |
| FDA-approved ipamorelin | Does not currently exist. |
| Compounded ipamorelin acetate | FDA has raised safety and characterization concerns. |
| Research-use ipamorelin | Not an FDA-approved consumer therapeutic product. |
| Online peptide ipamorelin | Higher risk for identity, sterility, dosing, and quality problems. |
How to evaluate ipamorelin claims online
| Claim | What to verify |
|---|---|
| “FDA-approved ipamorelin” | False. Ipamorelin is not FDA-approved. |
| “Boosts HGH naturally” | It can stimulate GH release, but that does not prove broad clinical benefit. |
| “Builds muscle and burns fat” | Look for controlled human outcome trials, not just GH biomarker changes. |
| “Anti-aging peptide” | Unsupported by strong clinical evidence. |
| “Improves sleep” | Check for controlled human trials, not anecdotes. |
| “No side effects” | False. FDA has identified immunogenicity and characterization concerns. |
| “Research use only” | This does not mean safe, legal, approved, or appropriate for human use. |
| “Safe for athletes” | False. Ipamorelin is prohibited in and out of competition. |
| “Same as sermorelin” | False. Ipamorelin works through ghrelin receptor signaling, while sermorelin is a GHRH analog. |
| “Third-party tested” | Ask for batch-specific HPLC, LC-MS, identity, purity, sterility, endotoxin, aggregate, and impurity data. |
Bottom line
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that mimics ghrelin and can stimulate pituitary growth hormone release. It has limited human evidence showing growth hormone release, but it is not FDA-approved and does not have strong clinical-outcome evidence for anti-aging, fat loss, muscle growth, sleep, injury recovery, or body recomposition.
The most defensible conclusion is:
Ipamorelin is biologically active and clinically interesting, but most online wellness, physique, and anti-aging claims go beyond the strongest evidence. FDA has raised concerns about compounded ipamorelin acetate, and athletes should avoid it because ipamorelin is prohibited in and out of competition.
FAQ
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue. It mimics ghrelin and stimulates growth hormone release through the growth hormone secretagogue receptor.
What does ipamorelin do?
Ipamorelin can stimulate the pituitary gland to release growth hormone. However, that does not prove broad anti-aging, fat-loss, muscle-building, sleep, or recovery benefits.
Is ipamorelin FDA-approved?
No. Ipamorelin is not FDA-approved. FDA has raised concerns about compounded ipamorelin acetate, including immunogenicity, aggregation, peptide-related impurities, unnatural amino acids, and characterization complexity.
Is ipamorelin the same as sermorelin?
No. Ipamorelin is a ghrelin receptor agonist and growth hormone secretagogue. Sermorelin is a growth hormone-releasing hormone analog.
Is ipamorelin the same as CJC-1295?
No. Ipamorelin works through ghrelin receptor/GHSR signaling. CJC-1295 is a GHRH analog.
Does ipamorelin build muscle?
Muscle-building claims are not well established. Ipamorelin can increase growth hormone release, but that does not prove safe or reliable muscle growth in healthy adults.
Does ipamorelin burn fat?
Fat-loss claims are mostly extrapolated from growth hormone biology. Ipamorelin is not FDA-approved as a fat-loss medication.
Does ipamorelin improve sleep?
Sleep claims are common online, but strong human clinical evidence is limited.
Is ipamorelin safe?
Ipamorelin does not have enough long-term human safety data to call it safe. FDA has raised concerns about immunogenicity, aggregation, peptide impurities, unnatural amino acids, and characterization complexity for compounded ipamorelin acetate.
Is ipamorelin banned in sports?
Yes. Ipamorelin is prohibited in and out of competition as a growth hormone secretagogue.
Why do sellers call ipamorelin “research use only”?
Sellers often use “research use only” language because ipamorelin is not FDA-approved for consumer therapeutic use. The phrase does not make the product safe, legal, approved, or clinically proven.
What is the biggest risk with ipamorelin?
The biggest risks are using an unapproved hormone-active peptide without medical supervision, relying on unsupported anti-aging or performance claims, and buying online products with uncertain identity, purity, sterility, concentration, and safety.
Sources
- FDA: Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks
- FDA: October 2024 PCAC Briefing Document on Ipamorelin and Related Peptides
- National Cancer Institute: Definition of Ipamorelin
- PubMed: Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin in Healthy Volunteers
- PubMed: Ipamorelin, a New Growth-Hormone-Releasing Peptide
- PubMed: GH Secretagogues Ipamorelin and GHRP-6 Increase Bone Mineral Content in Rats
- Sport Integrity Australia: Ipamorelin Information
- WADA: 2025 Prohibited List
- WADA: Prohibited List
- USADA: David Branch Receives Doping Sanction
Frequently asked questions
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue. It mimics ghrelin and stimulates growth hormone release through the growth hormone secretagogue receptor.
Is ipamorelin FDA-approved?
No. Ipamorelin is not FDA-approved. FDA has raised concerns about compounded ipamorelin acetate, including immunogenicity, aggregation, peptide-related impurities, unnatural amino acids, and characterization complexity.
Is ipamorelin the same as sermorelin?
No. Ipamorelin is a ghrelin receptor agonist and growth hormone secretagogue. Sermorelin is a growth hormone-releasing hormone analog.
Does ipamorelin build muscle?
Muscle-building claims are not well established. Ipamorelin can increase growth hormone release, but that does not prove safe or reliable muscle growth in healthy adults.
Is ipamorelin safe?
Ipamorelin does not have enough long-term human safety data to call it safe. FDA has raised concerns about immunogenicity, aggregation, peptide impurities, unnatural amino acids, and characterization complexity for compounded ipamorelin acetate.
Is ipamorelin banned in sports?
Yes. Ipamorelin is prohibited in and out of competition as a growth hormone secretagogue.
Sources
- [1]
- [2]
- [3]National Cancer Institute: Definition of Ipamorelin
Medical Reference
- [4]
- [5]
- [6]
- [7]
- [8]WADA: 2025 Prohibited List
Anti Doping
- [9]WADA: Prohibited List
Anti Doping
- [10]USADA: David Branch Receives Doping Sanction
Anti Doping
Last updated May 9, 2026